Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Reardon, D; Akabani, G; Friedman, A; Friedman, H; Herndon, J; McLendon, R; Quinn, J; Rich, J; Vredenburgh, J; Penne, K; Sampson, J; Gururangan, S; Shafman, T; Wong, T; Dowell, J; Dunn, R; Badruddoja, M; Desjardins, A; Affronti, M; Allen, D; Jackson, S; Zeigler, K; Silverman, S; Tourt-Uhlig, S; Coleman, R; Zalutsky, N; Bigner, D

Published Date

  • October 1, 2004

Published In

Volume / Issue

  • 6 / 4

Start / End Page

  • 381 - 381

Published By


  • 1

International Standard Serial Number (ISSN)

  • 1522-8517

Conference Name

  • 9th Annual Meeting of the Society-for-Neuro-Oncology

Conference Location

  • Toronto, CANADA

Conference Start Date

  • November 18, 2004

Conference End Date

  • November 21, 2004